A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Why is the prima study being done?

Mother and daughterThe trial will look at how well niraparib works compared with placebo as maintenance treatment in patients with Stage III or IV ovarian cancer (including fallopian and peritoneal cancers) following front-line platinum-based chemotherapy.

  • All Stage IV patients are eligible, regardless of remaining disease, after primary or interval debulking. Stage III patients must have visible remaining disease after primary surgery. Patients with inoperable Stage III and IV disease are eligible.
  • Patient must have a complete response or partial response following completion of their first line platinum based chemotherapy.
  • Patient must be randomized within 12 weeks of the first day of their last cycle of chemotherapy.
  • Must not have had treatment with a known PARP inhibitor or participated in a study where any treatment arm included a known PARP inhibitor.
  • Must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • Must not be pregnant, breastfeeding, or expecting to conceive children while on study treatment and for 180 days after the last dose of study treatment.


The best next step is to contact the research site that would be the most convenient for you in order to discuss your medical history and whether the PRIMA clinical trial would be a good fit.

To find sites in your area, contact: clinicaltrials@tesarobio.com or use the form above.

To find additional information on PRIMA see: clinicaltrials.gov

To find a Prima triAl site near you, enter your email address and zip code below:



Additional Resources

About PARP Inhibitors

Clinical Trials FAQ

Prima FAQ

About Ovarian Cancer